Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Max Biopharma Inc. holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, the portfolio includes 1 pending office action. This action is located within 1 distinct art unit, suggesting a narrow technical scope for the company's active patent applications. The focus on a single pending matter indicates a concentrated effort to protect a specific pharmaceutical or biotechnological development.
The prosecution is managed by 1 distinct examiner, SEITZ, ANTHONY JOSEPH. As the busiest examiner, SEITZ, ANTHONY JOSEPH is responsible for 1 pending office action. This examiner is the only one currently reviewing the company's pending intellectual property. With 1 pending office action assigned to 1 distinct examiner, the company's prosecution path is centralized, requiring a focused approach to address the specific requirements of this examiner. Practitioners should analyze the preferences of SEITZ, ANTHONY JOSEPH within the 1 distinct art unit to effectively advance the company's patent goals.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEITZ, ANTHONY JOSEPH | 1 | 67.8% | +27.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033885 | METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASES | SEITZ, ANTHONY JOSEPH | 31d overdue |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18033885 | METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASES | SEITZ, ANTHONY JOSEPH | 1629 | §103 | Final Rejection | 31d overdue | Pending | Apr 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMax Biopharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Anthony Joseph Seitz has the most, with 1 of Max Biopharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
